Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Revenue (2022 - 2025)

Historic Revenue for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $32.5 million.

  • ARS Pharmaceuticals' Revenue rose 147161.51% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.8 million, marking a year-over-year increase of 545965.73%. This contributed to the annual value of $89.1 million for FY2024, which is 29706333.33% up from last year.
  • ARS Pharmaceuticals' Revenue amounted to $32.5 million in Q3 2025, which was up 147161.51% from $15.7 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Revenue peaked at $86.6 million during Q4 2024, and registered a low of $10000.0 during Q2 2023.
  • For the 4-year period, ARS Pharmaceuticals' Revenue averaged around $13.3 million, with its median value being $663000.0 (2022).
  • As far as peak fluctuations go, ARS Pharmaceuticals' Revenue crashed by 9784.48% in 2023, and later skyrocketed by 490000.0% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Revenue (Quarter) stood at $189000.0 in 2022, then plummeted by 94.71% to $10000.0 in 2023, then soared by 865710.0% to $86.6 million in 2024, then tumbled by 62.46% to $32.5 million in 2025.
  • Its Revenue was $32.5 million in Q3 2025, compared to $15.7 million in Q2 2025 and $8.0 million in Q1 2025.